Provided herein are glucagon analogs which exhibit potent activity at the GIP receptor, and, as such are contemplated for use in treating diabetes and obesity. In exemplary embodiments, the glucagon analog of the present disclosures exhibit an EC50 at the GIP receptor which is within the nanomolar or picomolar range.
申请公布号
WO2012088116(A3)
申请公布日期
2012.11.15
申请号
WO2011US66164
申请日期
2011.12.20
申请人
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION;DIMARCHI, RICHARD, D.;WARD, BRIAN
